Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lunai BioworksSTU:2Q5 26 Quick Ratio is 0.19 as of Mar. 2026, which is 85% below its 10-year median of 1.31. GuruFocus rates STU:2Q5 with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 1,409 Biotechnology companies, Lunai Bioworks ranks worse than 94.61% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Lunai Bioworks's quick ratio for the quarter that ended in Mar. 2026 was 0.19.
Lunai Bioworks has a quick ratio of 0.19. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Lunai Bioworks's Quick Ratio or its related term are showing as below:
STU:2Q5'
s Quick Ratio Range Over the Past 10 Years
Min: 0.03 Med: 1.31 Max: 18.84
Current: 0.19
During the past 13 years, Lunai Bioworks's highest Quick Ratio was 18.84. The lowest was 0.03. And the median was 1.31.
STU:2Q5's Quick Ratio is ranked worse than 94.61% of 1409
companies
in the Biotechnology industry
Industry Median: 3.59
vs STU:2Q5: 0.19
Lunai Bioworks (STU:2Q5) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lunai Bioworks Quick Ratio Related Terms
Lunai Bioworks Quick Ratio Historical Data
* Premium members only.
The historical data trend for Lunai Bioworks's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2Q5 vs BCLI, BIVI, XCUR: Quick Ratio Comparison
For the Biotechnology subindustry, Lunai Bioworks's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lunai Bioworks Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lunai Bioworks's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lunai Bioworks's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Lunai Bioworks's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lunai Bioworks (STU:2Q5) has a Quick Ratio of 0.19 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lunai Bioworks and its competitors. This is 85% below median its historical median of 1.31. Over the past decade, Lunai Bioworks' Quick Ratio has ranged from 0.03 to 18.84. According to the industry distribution chart, Lunai Bioworks ranks #1333 out of 1409 companies in the Biotechnology industry, placing it in the top 94.6%.
Is Lunai Bioworks' Quick Ratio too high?
Lunai Bioworks' current Quick Ratio of 0.19 is 85% below median its 10-year median of 1.31. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 18.84. The Biotechnology industry median Quick Ratio is 3.59. Lunai Bioworks' value of 0.19 is 94.7% below this industry median. Based on the distribution chart, Lunai Bioworks ranks #1333 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lunai Bioworks has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lunai Bioworks' Quick Ratio compare to BCLI and BIVI?
According to the Biotechnology industry distribution chart, Lunai Bioworks ranks #1333 out of 1409 companies for Quick Ratio. This places Lunai Bioworks in the lower half of its industry. The industry median Quick Ratio is 3.59. Lunai Bioworks' value of 0.19 is 94.7% below this benchmark. Historically, Lunai Bioworks' own Quick Ratio has ranged from 0.03 to 18.84 over the past decade. While the company's 10-year median is 1.31 vs. the industry median of 3.59, Lunai Bioworks has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lunai Bioworks's current Quick Ratio of 0.19 is 94.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lunai Bioworks and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lunai Bioworks's current Quick Ratio is 0.19, which is 85% below median its own 10-year median of 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lunai Bioworks stock overvalued right now?
Lunai Bioworks (STU:2Q5) has a current Quick Ratio of 0.19. The current Quick Ratio is 0.19, which is 85% below median its 10-year median of 1.31 and 94.7% below the Biotechnology industry median of 3.59. Lunai Bioworks' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lunai Bioworks (STU:2Q5), the current Quick Ratio is 0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
26GF Score
Get the complete analysis for STU:2Q5
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2Q5 has been successfully added to your 
